CSL Limited Surges: Strong Market Cap, Resilient Growth Despite Negative P/E
CSL Limited: Resilient biotech leader in human plasma products, rebounding to AUD 196.7, backed by a $94B market cap and innovation‑driven growth.
2 minutes to read
CSL LIMITED